AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30337695 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal phalloplasty (DP) with penile prosthesis implantation
Number of subjects: 126
Study 30337695 — intervention group
Group type: COMPARATOR
Intervention: Penile prosthesis alone (Control)
Number of subjects: 126
Study 28579538 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 127
Study 28579538 — intervention group
Group type: COMPARATOR
Intervention: Sham endoscopic procedure
Number of subjects: 127
Study 25939657 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 81 mg aspirin for 14 days before exercise and a single dose of 325 mg aspirin immediately after exertion
Number of subjects: 52
Study 25939657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin before exertion
Number of subjects: 52
Study 25939657 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose aspirin after exertion
Number of subjects: 52
Study 24719046 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (3 exercise sessions per week for 3 months at 70% VO2MAX)
Number of subjects: 19
Study 24719046 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 19
Study 23285043 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure variability (measured as standard deviation)
Number of subjects: 5804
Study 23285043 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in diastolic blood pressure
Number of subjects: 5804
Study 23285043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure variability
Number of subjects: 5804
Study 20098295 — intervention group
Group type: EXPERIMENTAL
Intervention: Carraguard vaginal gel
Number of subjects: 60
Study 20098295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcellulose placebo
Number of subjects: 60
Study 20098295 — intervention group
Group type: COMPARATOR
Intervention: No product
Number of subjects: 60
Study 18038224 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine
Number of subjects: 15
Study 18038224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18038224 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg quetiapine (after 5 days of daily intake)
Number of subjects: 15
Study 15951127 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-part treatment intervention aimed to reduce long-term benzodiazepine use
Number of subjects: 0
Study 15951127 — intervention group
Group type: COMPARATOR
Intervention: Patients still using benzodiazepines
Number of subjects: 0
Study 15951127 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had received additional tapering off
Number of subjects: 0
Study 15951127 — intervention group
Group type: COMPARATOR
Intervention: Patients who had quit benzodiazepine use after one of the two interventions
Number of subjects: 0
Study 12517654 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast medium
Number of subjects: 56
Study 12517654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional contrast medium)
Number of subjects: 56
Study 11120733 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6
Number of subjects: 0
Study 11120733 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 0
Study 11120733 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 0
Study 9259652 — intervention group
Group type: COMPARATOR
Intervention: 160 mg aspirin
Number of subjects: 8803
Study 9259652 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg warfarin with 80 mg aspirin
Number of subjects: 8803
Study 9259652 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg warfarin with 80 mg aspirin
Number of subjects: 8803
Study 8272491 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons wearing sterile gloves
Number of subjects: 124
Study 8272491 — intervention group
Group type: COMPARATOR
Intervention: Surgeons wearing nonsterile, but clean gloves
Number of subjects: 124
Study 3614964 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg in 10 ml glucose solution)
Number of subjects: 12
Study 3614964 — intervention group
Group type: COMPARATOR
Intervention: Morphine (3 mg in 10 ml glucose solution)
Number of subjects: 12
Study 30572548 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) combined with conventional rehabilitation therapy
Number of subjects: 82
Study 30572548 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy only
Number of subjects: 82
Study 27206212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1μg/kg 10min before anesthesia induction, maintain dose 0.4μg/(kg/h))
Number of subjects: 60
Study 27206212 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 60
Study 24406474 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning-only polyethylene glycol (PEG)
Number of subjects: 120
Study 24406474 — intervention group
Group type: COMPARATOR
Intervention: Split-dose polyethylene glycol (PEG)
Number of subjects: 120
Study 22414509 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalase‐based neutralizer gel applied for three minutes
Number of subjects: 30
Study 22414509 — intervention group
Group type: COMPARATOR
Intervention: 10% carbamide peroxide bleaching agent
Number of subjects: 30
Study 22414509 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleached specimens with catalase‐based gel
Number of subjects: 30
Study 22414509 — intervention group
Group type: COMPARATOR
Intervention: Nonbleached negative control specimens
Number of subjects: 30
Study 22414509 — intervention group
Group type: COMPARATOR
Intervention: Bleached positive control specimens
Number of subjects: 30
Study 20708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.5% lidocaine
Number of subjects: 40
Study 20708510 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 1% lidocaine
Number of subjects: 40
Study 18093572 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisals of intrusive thoughts (personal significance rating)
Number of subjects: 0
Study 18093572 — intervention group
Group type: EXPERIMENTAL
Intervention: Appraisals of socially unacceptable thoughts
Number of subjects: 0
Study 18093572 — intervention group
Group type: EXPERIMENTAL
Intervention: Relation of appraisals to OC symptoms
Number of subjects: 0
Study 15990754 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy (90Sr/90Y beta-radiation)
Number of subjects: 476
Study 15990754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonactive source train)
Number of subjects: 476
Study 12848635 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole
Number of subjects: 27
Study 12848635 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole
Number of subjects: 27
Study 10096266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 102
Study 10096266 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 500 mg
Number of subjects: 102
Study 10096266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 102
Study 10096266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 8769696 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α
Number of subjects: 139
Study 8769696 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-α/ara-C
Number of subjects: 139
Study 8425237 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 65
Study 8425237 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 75 mg
Number of subjects: 65
Study 8425237 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of sedation and memory test
Number of subjects: 65
Study 2949584 — intervention group
Group type: EXPERIMENTAL
Intervention: PN 200-110 (isradipine) combined with pindolol
Number of subjects: 61
Study 29920440 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (n=15)
Number of subjects: 30
Study 29920440 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (n=15)
Number of subjects: 30
Study 27741334 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate 0.05% gel
Number of subjects: 24
Study 27741334 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 24
Study 27741334 — intervention group
Group type: COMPARATOR
Intervention: Reference skin
Number of subjects: 24
Study 24946835 — intervention group
Group type: EXPERIMENTAL
Intervention: Low right atrial septal (LRAS) pacing
Number of subjects: 102
Study 24946835 — intervention group
Group type: COMPARATOR
Intervention: Right atrial appendage (RAA) pacing
Number of subjects: 102
Study 22705219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography (CBCT)
Number of subjects: 79
Study 22705219 — intervention group
Group type: COMPARATOR
Intervention: Dental panoramic radiography (PAN)
Number of subjects: 79
Study 22705219 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 79
Study 22705219 — intervention group
Group type: COMPARATOR
Intervention: PAN
Number of subjects: 79
Study 20540264 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior subcutaneous transposition
Number of subjects: 66
Study 20540264 — intervention group
Group type: COMPARATOR
Intervention: Anterior submuscular transposition
Number of subjects: 66
Study 19326771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sobrietol (amethystic product)
Number of subjects: 2
Study 19326771 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 2
Study 15736108 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/d)
Number of subjects: 0
Study 15736108 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg bid)
Number of subjects: 0
Study 12773445 — intervention group
Group type: EXPERIMENTAL
Intervention: HP hMG
Number of subjects: 100
Study 10813592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise ventilation and cardiac output in prematurely born children
Number of subjects: 32
Study 10813592 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise with measurement of cardiac output (indirect [CO2] Fick)
Number of subjects: 32
Study 10813592 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic dead space normalized for body weight
Number of subjects: 32
Study 10813592 — intervention group
Group type: COMPARATOR
Intervention: Heart rate-VO2 relationship and stroke volume
Number of subjects: 32
Study 9014745 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose melphalan with G-CSF-primed unprocessed whole blood
Number of subjects: 30
Study 9014745 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 30
Study 2061776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 29
Study 2061776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6760969 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of cefuroxime prophylaxis (0.75 gm 30 to 60 minutes before surgery and at 8 hours and 16 hours after surgery)
Number of subjects: 60
Study 6760969 — intervention group
Group type: EXPERIMENTAL
Intervention: Five days of cefuroxime prophylaxis (0.75 gm three times a day, the first dose being given postoperatively)
Number of subjects: 60
Study 6760969 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (control group)
Number of subjects: 60
Study 31322914 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression, anti-arrhythmic medications, heart failure medications, device therapy, ablation therapy, heart transplantation
Number of subjects: 0
Study 31322914 — intervention group
Group type: COMPARATOR
Intervention: Screening for cardiac sarcoidosis
Number of subjects: 0
Study 29330636 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P6 (6 mg/kg, 90 min intravenous infusion)
Number of subjects: 70
Study 29330636 — intervention group
Group type: COMPARATOR
Intervention: Reference trastuzumab (6 mg/kg, 90 min intravenous infusion)
Number of subjects: 70
Study 26589462 — intervention group
Group type: EXPERIMENTAL
Intervention: Backboard
Number of subjects: 43
Study 26589462 — intervention group
Group type: COMPARATOR
Intervention: No backboard
Number of subjects: 43
Study 25403211 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer-support intervention (IG)
Number of subjects: 337
Study 22088571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 60
Study 22088571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 19445704 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Number of subjects: 4500
Study 19445704 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned early delivery at 37-38 weeks
Number of subjects: 4500
Study 19445704 — intervention group
Group type: COMPARATOR
Intervention: Trial recruitment rate
Number of subjects: 4500
Study 19445704 — intervention group
Group type: COMPARATOR
Intervention: Spectrum of disease among recruits and non-recruits
Number of subjects: 4500
Study 19445704 — intervention group
Group type: COMPARATOR
Intervention: Compliance with treatment allocations
Number of subjects: 4500
Study 17784946 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal intervention group receiving prevention consultations by GP with personalized feedback and intensive support for health behaviour change.
Number of subjects: 350
Study 17784946 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention group receiving prevention consultations using a cardiovascular risk calculator and general feedback.
Number of subjects: 350
Study 17784946 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal intervention group
Number of subjects: 350
Study 17784946 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 350
Study 15097246 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (20 mg/day for 4 weeks)
Number of subjects: 2
Study 15097246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 12234947 — intervention group
Group type: EXPERIMENTAL
Intervention: DL‐alpha‐tocopherol 400 IU per day
Number of subjects: 0
Study 12234947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9652433 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (1.6 x 10(8) cfu)
Number of subjects: 76
Study 9652433 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (3.2 x 10(8) cfu)
Number of subjects: 76
Study 9652433 — intervention group
Group type: COMPARATOR
Intervention: Very low dose (1.6 x 10(5) cfu)
Number of subjects: 76
Study 9652433 — intervention group
Group type: COMPARATOR
Intervention: Low dose (3.2 x 10(6) cfu)
Number of subjects: 76
Study 8205868 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily regimen A: 500 micrograms in the morning and at bedtime
Number of subjects: 42
Study 8205868 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose regimen B: 1,000 micrograms in the late afternoon
Number of subjects: 42
Study 8205868 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose regimen C: 1,000 micrograms at bedtime
Number of subjects: 42
Study 2643914 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of zidovudine at various rates (0.5, 0.9, 1.4, 1.8 mg/kg body weight per hour)
Number of subjects: 21
Study 2643914 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of zidovudine
Number of subjects: 21
Study 2643914 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of zidovudine (80 mg/m2 over 1 hour)
Number of subjects: 21
Study 936954 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cephalothin at the induction of anesthesia and another 2 g, 5 and 10 hours after the primary infusion (treatment group)
Number of subjects: 0
Study 936954 — intervention group
Group type: COMPARATOR
Intervention: Control group remained untreated
Number of subjects: 0
Study 30395961 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate and carboxymethyl cellulose solution (HA‐CMC sol)
Number of subjects: 44
Study 30395961 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids and local anesthetics (control group)
Number of subjects: 44
Study 28740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary FA intervention for 12 weeks
Number of subjects: 442
Study 28740125 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 442
Study 28740125 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plasma n-3 PUFA
Number of subjects: 442
Study 28740125 — intervention group
Group type: EXPERIMENTAL
Intervention: High proportion of plasma C16:0
Number of subjects: 442
Study 26156665 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling drain (group A)
Number of subjects: 43
Study 26156665 — intervention group
Group type: COMPARATOR
Intervention: No indwelling drain (group B)
Number of subjects: 43
Study 26156665 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling drain (group A) and No indwelling drain (group B)
Number of subjects: 43
Study 23819600 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention in cardiovascular prevention
Number of subjects: 75000
Study 23819600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 75000
Study 21767016 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-related intervention (plus usual care)
Number of subjects: 70
Study 21767016 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 70
Study 18438228 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental energy patches
Number of subjects: 41
Study 18438228 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 41
Study 16406076 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact diode laser myringotomy (CDLM)
Number of subjects: 30
Study 16406076 — intervention group
Group type: COMPARATOR
Intervention: Myringotomy with tube insertion (M&T)
Number of subjects: 30
Study 14632856 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergic treatment (group 1) for 6 months
Number of subjects: 75
Study 14632856 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for SUI (group 2)
Number of subjects: 75
Study 14632856 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3) with pure SUI
Number of subjects: 75
Study 10704958 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 9
Study 10704958 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg
Number of subjects: 9
Study 10704958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9067537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization with DPCP on non-UV-exposed normal skin
Number of subjects: 46
Study 9067537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization with DPCP on skin exposed to three MED of UVB radiation
Number of subjects: 46
Study 9067537 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitization with DPCP on skin exposed to three MED of UVA radiation
Number of subjects: 46
Study 9067537 — intervention group
Group type: COMPARATOR
Intervention: No sensitization
Number of subjects: 46
Study 8180325 — intervention group
Group type: EXPERIMENTAL
Intervention: Reviparin-sodium (1,750 anti-Xa IU once a day in the morning followed by placebo in the evening for at least 6 days)
Number of subjects: 1351
Study 8180325 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 U twice a day for at least 6 days)
Number of subjects: 1351
Study 3724174 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine therapy
Number of subjects: 0
Study 3724174 — intervention group
Group type: COMPARATOR
Intervention: Nonthyroxine treatment (control group)
Number of subjects: 0
Study 29244111 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline serum albumin (per 1 g/dL)
Number of subjects: 4576
Study 29244111 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline serum albumin
Number of subjects: 4576
Study 27270900 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stretching (no-MVC session)
Number of subjects: 11
Study 27270900 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stretching (MVC session)
Number of subjects: 11
Study 24457527 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus aerobic exercise (D/Ex)
Number of subjects: 75
Study 24457527 — intervention group
Group type: COMPARATOR
Intervention: Diet only (DO)
Number of subjects: 75
Study 22560101 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen via nonrebreather mask at 15 L/min for 15 minutes
Number of subjects: 204
Study 22560101 — intervention group
Group type: COMPARATOR
Intervention: Room air via nonrebreather mask for 15 minutes (placebo)
Number of subjects: 204
Study 20530280 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of trastuzumab treatment
Number of subjects: 3401
Study 20530280 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 3401
Study 18845993 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Breast Irradiation (WBI)
Number of subjects: 29
Study 18845993 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Breast Irradiation (PBI)
Number of subjects: 29
Study 16189633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcitriol pulse therapy
Number of subjects: 46
Study 16189633 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous OCT
Number of subjects: 46
Study 16189633 — intervention group
Group type: COMPARATOR
Intervention: Intravenous OCT in refractory patients
Number of subjects: 46
Study 12505809 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 175
Study 12505809 — intervention group
Group type: COMPARATOR
Intervention: Nonobese patients
Number of subjects: 175
Study 10955749 — intervention group
Group type: EXPERIMENTAL
Intervention: 85% exercise load
Number of subjects: 20
Study 10955749 — intervention group
Group type: EXPERIMENTAL
Intervention: 95% exercise load
Number of subjects: 20
Study 8860065 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐interferon (3 x 10(6) IM for 2 months and consecutive 6 x 10(6) IM for 10 months) every second evening
Number of subjects: 26
Study 8860065 — intervention group
Group type: COMPARATOR
Intervention: aspecific treatment
Number of subjects: 26
Study 8860065 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐interferon
Number of subjects: 26